1.
Bioorg Med Chem Lett
; 19(15): 4471-5, 2009 Aug 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-19501510
RESUMO
COPD is a major cause of mortality in the western world. A(2A) agonists are postulated to reduce the lung inflammation that causes COPD. The cardiovascular effects of A(2A) agonists dictate that a compound needs to be delivered by inhalation to be therapeutically useful. The pharmacological and pharmacokinetic SAR of a series of inhaled A(2A) agonists is described leading through to human pharmacokinetic data for a clinical candidate.